|Headquarters||San Diego, California, U.S.|
|Gene Lay, D.V.M., Founder and CEO|
|Products||Antibodies, ELISA Kits and Sets, Recombinant Proteins, Custom Assay Development, Buffers and Solutions|
BioLegend is a global developer and manufacturer of antibodies and reagents used in biomedical research located in San Diego, California. It was incorporated in June 2002 and has since expanded to include BioLegend Japan KK, where it is partnered with Tomy Digital Biology Co., Ltd. in Tokyo, BioLegend Europe in the United Kingdom, BioLegend GmbH in Germany, and BioLegend UK Ltd in the United Kingdom. BioLegend manufactures products in the areas of cell immunophenotyping, cytokines and chemokines, adhesion, cancer research, T regulatory cells, stem cells, innate immunity, cell-cycle analysis, apoptosis, and modification-specific antibodies. Reagents are created for use in flow cytometry, ELISA, immunoprecipitation, Western blotting, immunofluorescence microscopy, immunohistochemistry, and in vitro or in vivo functional assays.
BioLegend was founded by CEO, Gene Lay, D.V.M., who was also the co-founder of PharMingen. BioLegend was created by demands from researchers who felt disenfranchised after the acquisition of PharMingen by BD Biosciences, feeling that it lacked the collaborative and customer-centric focus that many had come to know. In 2011, BioLegend co-developed and introduced Brilliant Violet(TM)-conjugated antibodies, using a novel fluorophore based on Nobel Prize-winning chemistry developed by Sirigen.